Roivant Sciences

Roivant Sciences is an American multinational healthcare company founded in 2014. It develops and delivers medicines and technologies through a decentralized model that builds and operates focused subsidiaries, known as Vants. More than 20 such subsidiaries have been created, several of which have gone on to become public companies. The group has raised over $6 billion in capital and generated more than $10 billion in proceeds from global pharmaceutical partnerships.

The company's record includes eight FDA approvals and 12 consecutive positive Phase 3 trials since 2019. Its work spans drug development, clinical development, pharmaceutical commercialization, biotechnology and therapeutic research, with activity in immunology, pulmonary diseases and rare diseases. VTAMA (tapinarof) cream, 1%, an FDA-approved topical treatment for plaque psoriasis in adults, launched in 2022.

Roivant employs scientists, development experts, investors, entrepreneurs and engineers, and states an emphasis on speed in bringing medicines to patients. It operates from New York City and Basel, Switzerland. The company describes its purpose as improving health by reinventing how the industry discovers, develops and delivers medicines.